Expansion Opportunity Pegasus has recently expanded facilities in Pensacola and increased headcount with a major hiring push, signaling capacity growth and readiness for new CDMO collaborations in manufacturing, QC, and R&D tied to animal health products.

Acquisition Momentum The acquisition of TriviumVet and ongoing pivotal clinical trials indicate an active growth trajectory and potential for strategic partnerships in veterinary pharma development and commercialisation across additional sites and product lines.

Veterinary Focus With a robust portfolio in animal health and distribution of PRN Pharmacal branded products, there is a clear pathway to partner on formulation development, regulatory support, and scale-up for companion animal and livestock therapeutics.

Full-Service CDMO As a cGMP and DEA-approved full-service CDMO offering end-to-end development, process transfer, and manufacturing, Pegasus is positioned to engage clients seeking turnkey solutions from concept to commercialization.

Strategic Partnerships Leadership changes and reported revenue growth combined with an enterprise-wide employee-ownership culture present a compelling value proposition for long-term collaborations with risk-sharing customers seeking stable, customer-centric partners.